Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)

-44.84% (1Y)

Market Cap	391.85M
Revenue (ttm)	216.45M
Net Income (ttm)	32.88M
Shares Out	n/a
EPS (ttm)	0.79
PE Ratio	11.92
Forward PE	n/a
Dividend	20.20 (215.81%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	n/a
Open	9.36
Previous Close	9.36
Day's Range	9.36 - 9.36
52-Week Range	9.36 - 16.97
Beta	-0.33
RSI	n/a
Earnings Date	Aug 5, 2025

About SBLOF

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,436
• Stock Exchange: OTCMKTS
• Ticker Symbol: SBLOF

Financial Performance

In 2024, SBLOF's revenue was 32.41 billion, an increase of 22.54% compared to the previous year's 26.45 billion. Earnings were 4.92 billion, a decrease of -10.97%.

Financial numbers in JPY